Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
21:14:51 EST Fri 23 Jan 2026
Enter Symbol
or Name
USA
CA



Q:RCKT - ROCKET PHARMACEUTICALS INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
RCKT - Q0.13.50·3.900.13.72-0.06-1.62,411.68,5018,5123.80  3.89  3.6911.45  2.1919:50:30Jan 0515 min RT 2¢

Recent Trades - Last 10 of 8512
Time ETExPriceChangeVolume
19:50:30Q3.76-0.02600
17:35:08Q3.72-0.0611,666
17:14:48Q3.72-0.06272
16:56:46Q3.755-0.0251
16:48:32Q3.76-0.0299
16:45:58Q3.76-0.02150
16:10:05Q3.72-0.061
16:10:05Q3.72-0.061
16:10:04Q3.72-0.061
16:10:04Q3.72-0.061

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-01-05 07:00U:RCKTNews ReleaseRocket Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference
2025-12-09 11:57U:RCKTNews ReleaseBeyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions
2025-11-25 07:00U:RCKTNews ReleaseRocket Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference
2025-11-06 16:00U:RCKTNews ReleaseRocket Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Progress
2025-10-14 07:00U:RCKTNews ReleaseRocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission of KRESLADI(TM) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)
2025-10-10 16:00U:RCKTNews ReleaseRocket Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-08-28 07:00U:RCKTNews ReleaseRocket Pharmaceuticals to Participate in Upcoming Investor Conferences
2025-08-20 07:00U:RCKTNews ReleaseRocket Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on the Pivotal Phase 2 Trial of RP-A501 for the Treatment of Danon Disease
2025-08-07 16:00U:RCKTNews ReleaseRocket Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Progress
2025-07-24 07:00U:RCKTNews ReleaseRocket Pharmaceuticals Announces Strategic Corporate Reorganization and Pipeline Prioritization of Cardiovascular Programs
2025-07-17 07:00U:RCKTNews ReleaseRocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A601 Gene Therapy for PKP2-Arrhythmogenic Cardiomyopathy
2025-06-30 07:00U:RCKTNews ReleaseRocket Pharmaceuticals Announces FDA IND Clearance of RP-A701 for the Treatment of BAG3-associated Dilated Cardiomyopathy
2025-05-27 07:00U:RCKTNews ReleaseRocket Pharmaceuticals Provides Update on Phase 2 Clinical Trial of RP-A501 for Danon Disease
2025-05-15 15:15U:RCKTNews ReleaseRocket Pharmaceuticals Presents Preliminary Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy at 28th Annual Meeting of the American Society of Gene and Cell Therapy
2025-05-09 16:30U:RCKTNews ReleaseRocket Pharmaceuticals Announces Late-Breaking Oral Presentation of Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy Accepted at 28th Annual Meeting of the American Society of Gene and Cell Therapy
2025-05-08 16:01U:RCKTNews ReleaseRocket Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Progress
2025-04-03 07:00U:RCKTNews ReleaseRocket Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference
2025-02-27 16:01U:RCKTNews ReleaseRocket Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress